Network Meta-Analysis (Nma) Comparing The Efficacy Of Enzalutamide Versus Apalutamide, Darolutamide, And Bicalutamide For Treatment Of Nonmetastatic (Nm) Castration-Resistant Prostate Cancer (Crpc).

Tomasz M. Beer,Fred Saad,Cora N. Sternberg,Maha H. A. Hussain,Arijit Ganguli, Hemant Singh Bhadauria,Mok Oh,Konstantina Skaltsa,Bertrand Tombal

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 4|浏览21

暂无评分

摘要

101Background: Enzalutamide is a potent androgen receptor (AR) inhibitor, targeting multiple steps in AR signaling. In recent years, the EMA and FDA approved enzalutamide for the management of adul...

查看译文

关键词

Enzalutamide,Apalutamide,Darolutamide,Bicalutamide,Prostate cancer,Androgen receptor,Oncology,Meta-analysis,Medicine,Castration resistant,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要